Cost-effectiveness of varenicline Versus Bupropion, Nicotine-Replacement Therapy, and Unaided Cessation in Greece

 
This item is provided by the institution :
Technological Educational Institute of Athens
Repository :
Ypatia - Institutional Repository
see the original item page
in the repository's web site and access all digital files if the item*
share




2012 (EN)
Cost-effectiveness of varenicline Versus Bupropion, Nicotine-Replacement Therapy, and Unaided Cessation in Greece (EN)

Ηγουμενίδης, Μιχαήλ (EL)
Βίτσου, Έλλη (EL)
Συκαρά, Γεωργία (EL)
Αθανασάκης, Κωνσταντίνος (EL)
Καραμπλή, Ελευθερία (EL)

Κυριόπουλος, Γιάννης Η. (1945-) (EL)
Τεχνολογικό Εκπαιδευτικό Ίδρυμα Αθήνας.Σχολή Επαγγελμάτων Υγείας και Πρόνοιας. Τμήμα Νοσηλευτικής. (EL)

Background Varenicline was designed to relieve symptoms of nicotine withdrawal, including cigarette craving, and to block the reinforcing effects of continued nicotine use. The cost-effectiveness of varenicline in some countries has not been studied. Objective The aim of this study was to compare the cost-effectiveness of varenicline to that of bupropion, nicotine-replacement therapy (NRT), and unaided cessation in the Greek health care setting. The analysis takes into account a societal security (third-party payer) perspective. Methods To perform the analyses of the benefits of smoking cessation in terms of smoking-related morbidity, mortality, and associated medical costs, a Markov model was used that simulated the progress of a hypothetical cohort of current smokers making a single attempt to quit smoking at the beginning of the timeframe of the analysis. The robustness of the results was assessed using a series of 1-way sensitivity analyses. Results Varenicline was associated with the potential prevention of 14.1, 14.2, and 35.1 additional cases of the 4 smoking-related diseases incorporated into the model, per 1000 smokers willing to quit, versus bupropion, NRT, and unaided cessation, respectively. Potentially avoided smoking-related deaths with varenicline were estimated at 3.24, 3.26, and 7.5 per 1000 quitters versus the 3 comparators. Varenicline led to a potential gain of 33.78, 33.91, and 83.97 QALYs per 1000 persons willing to make a quit attempt versus the 3 comparators. Varenicline was associated with cost-savings against both active comparators for the lifetime horizon. Overall, the cost per additional quitter with varenicline, considering only the costs of the smoking-cessation strategy, was €2659 (€1015) for a lifetime horizon compared with bupropion (NRT); however, when all direct costs were incorporated into the analysis, varenicline was cost-saving. Conclusion The findings from the present study suggest that, compared with the widely used treatment options bupropion and NRT, as well as unaided cessation, varenicline may enhance smoking-cessation treatment outcomes while substantially reducing the overall costs of smoking to the health care system. (EN)

journalArticle

Cost-effectiveness analysis (EN)
Ανάλυση κόστους-αποτελεσματικότητας (EN)
Κάπνισμα (EN)
Smoking (EN)

ΤΕΙ Αθήνας (EL)
Technological Educational Institute of Athens (EN)

Clinical Therapeutics (EN)

English

2012

doi:10.1016/j.clinthera.2012.07.002

Elsevier B.V. (EN)



*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)